The Editorial Process
A manuscript will be reviewed for possible publication with the understanding that it is being submitted to Egyptian Pharmaceutical Journal alone at that point in time and has not been published anywhere, simultaneously submitted, or already accepted for publication elsewhere. The submitted manuscripts should be copy-edited for grammar, punctuation, print style, and format. The journal expects that authors would authorize one of them to correspond with the Journal for all matters related to the manuscript. All manuscripts received are duly acknowledged. On submission, editors review all submitted manuscripts initially for suitability for formal review. Manuscripts with insufficient originality, serious scientific or technical flaws, or lack of a significant message are rejected before proceeding for formal peer-review. Manuscripts that are unlikely to be of interest to the Egyptian Pharmaceutical Journal readers are also liable to be rejected at this stage itself.
Manuscripts that are found suitable for publication in Egyptian Pharmaceutical Journal are sent to two or more expert reviewers. During submission, the contributor is requested to provide names of two or three qualified reviewers who have had experience in the subject of the submitted manuscript, but this is not mandatory. The reviewers should not be affiliated with the same institutes as the contributor/s. However, the selection of these reviewers is at the sole discretion of the editor. The journal follows a double-blind review process, wherein the reviewers and authors are unaware of each other's identity. Every manuscript is also assigned to a member of the editorial team, who based on the comments from the reviewers takes a final decision on the manuscript. The comments and suggestions (acceptance/ rejection/ amendments in manuscript) received from reviewers are conveyed to the corresponding author. If required, the author is requested to provide a point by point response to reviewers' comments and submit a revised version of the manuscript. This process is repeated till reviewers and editors are satisfied with the manuscript.
The corresponding author is expected to return the corrected proofs within three days. It may not be possible to incorporate corrections received after that period. The whole process of submission of the manuscript to final decision and sending and receiving proofs is completed online. To achieve faster and greater dissemination of knowledge and information, the journal publishes articles online as 'Ahead of Print' immediately on acceptance.
Clinical trial registry
Egyptian Pharmaceutical Journal would publish clinical trials that have been registered with a clinical trial registry that allows free online access to public. Registration in the following trial registers is acceptable: https://ctri.nic.in/Clinicaltrials/login.php, http://www.clinicaltrials.gov/, http://isrctn.org/ and http://www.umin.ac.jp/ctr. This is applicable to clinical trials that have begun enrollment of subjects in or after June 2008. Clinical trials that have commenced enrollment of subjects prior to June 2008 would be considered for publication in Egyptian Pharmaceutical Journal only if they have been registered retrospectively with clinical trial registry that allows unhindered online access to public without charging any fees.
Authorship Criteria
Authorship credit should be based only on substantial contributions to each of the three components mentioned below:
Participation solely in the acquisition of funding or the collection of data does not justify authorship. General supervision of the research group is not sufficient for authorship. Each contributor should have participated sufficiently in the work to take public responsibility for appropriate portions of the manuscript's content. The order of naming the contributors should be based on the relative contribution of the contributor towards the study and writing the manuscript. Once submitted the order cannot be changed without written consent of all the contributors. The journal prescribes a maximum number of authors for manuscripts depending upon the type of manuscript, its scope and the number of institutions involved (vide infra). The authors should provide a justification if the number of authors exceeds these limits.
Please print the Copyright Transfer Agreement (CTA) that is present here, complete and sign it from all authors’ of the article, scan it and upload it to the journal website.
Contribution Details
Contributors should provide a description of contributions made by each of them towards the manuscript. Description should be divided into the following categories: concept, design, the definition of intellectual content, literature search, clinical studies, experimental studies, data acquisition, data analysis, statistical analysis, manuscript preparation, manuscript editing and manuscript review. Authors' contributions will be printed along with the article. One or more authors should take responsibility for the integrity of the work as a whole from inception to published article and should be designated as 'guarantor'.
Conflicts of Interest/ Competing Interests
All authors of articles must disclose any and all conflicts of interest they may have with the publication of the manuscript or an institution or product that is mentioned in the manuscript and/or is important to the outcome of the study presented. Authors should also disclose conflicts of interest with products that compete with those mentioned in their manuscript.
Ahead of Print policy
Articles published online under the Ahead of Print model are considered published and can be cited and quoted using the DOI as the reference source.
Submission of Manuscripts
The submitted manuscripts that are not as per the “Instructions to Authors" would be returned to the authors for technical correction, before they undergo editorial/ peer-review. Generally, the manuscript should be submitted in the form of two separate files:
[1] Title Page/First Page File/covering letter:
This file should provide
[2] Manuscript file: The main text of the article, beginning from the Abstract till References (including tables) should be in this file. The file must not contain any mention of the authors' names or initials or the institution at which the study was done or acknowledgements. The running title should be included. Manuscripts not in compliance with the Journal's blinding policy will be returned to the corresponding author. Use doc files and do not zip the files. Limit the file size to 1 MB. Do not incorporate images in the file. If file size is large, graphs can be submitted as images separately without incorporating them in the article file to reduce the size of the file. The pages should be numbered consecutively.
[3] Images: Submit good-quality color images. Each image should be less than 2 MB in size. Size of the image can be reduced by decreasing the actual height and width of the images (keep up to 1600 x 1200 pixels or 5-6 inches). Images can be submitted as jpeg files. Do not zip the files. Legends for the figures/images should be included at the end of the article file.
[4] The contributors' / copyright transfer form (template provided below) has to be submitted in original with the signatures of all the contributors within two weeks of submission via courier, fax, or email as a scanned image. Print-ready hard copies of the images (one set) or digital images should be sent to the journal office at the time of submitting the revised manuscript. High-resolution images (up to 5 MB each) can be sent by email.
Types of Manuscripts
Original articles:
These include randomized controlled trials, intervention studies, studies of screening and diagnostic test, outcome studies, cost-effectiveness analyses, case-control series, and surveys with high response rate. The text of original articles should be divided into sections with the headings Abstract, Keywords, Introduction, Material and methods, Results anddiscussion (could be combined as “Results and Discussion”), Conclusion, and References, Tables and Figure legends.
Introduction: State the purpose and summarize the rationale for the study or observation.
Materials and methods: It should include and describe the following aspects:
Ethics: When reporting studies on human beings, indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional or regional) and with the Helsinki Declaration of 1975, as revised in 2000 (available at https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/). For prospective studies involving human participants, authors are expected to mention about approval of (regional/ national/ institutional or independent Ethics Committee or Review Board, obtaining informed consent from adult research participants and obtaining assent for children aged over 7 years participating in the trial. The age beyond which assent would be required could vary as per regional and/ or national guidelines. Ensure confidentiality of subjects by desisting from mentioning participants' names, initials or hospital numbers, especially in illustrative material. When reporting experiments on animals, indicate whether the institution's or a national research council's guide for, or any national law on the care and use of laboratory animals was followed.
Evidence for approval by a local Ethics Committee (for both human as well as animal studies) must be supplied by the authors on demand. Animal experimental procedures should be as humane as possible and the details of anesthetics and analgesics used should be clearly stated. The ethical standards of experiments must be in accordance with the guidelines provided by the CPCSEA and World Medical Association Declaration of Helsinki on Ethical Principles for Medical Research Involving Humans for studies involving experimental animals and human beings, respectively). The journal will not consider any paper which is ethically unacceptable. A statement on ethics committee permission, ethical approval number and ethical practices must be included in all research articles under the 'Materials and Methods' section.
Study design:
Selection and Description of Participants: Describe your selection of the observational or experimental participants (patients or laboratory animals, including controls) clearly, including eligibility and exclusion criteria and a description of the source population. Technical information: Identify the methods, apparatus (give the manufacturer's name and address in parentheses), and procedures in sufficient detail to allow other workers to reproduce the results. Give references to established methods, including statistical methods (see below); provide references and brief descriptions for methods that have been published but are not well known; describe new or substantially modified methods, give reasons for using them, and evaluate their limitations. Identify precisely all drugs and chemicals used, including generic name(s), dose(s), and route(s) of administration.
Reports of randomized clinical trials should present information on all major study elements, including the protocol, assignment of interventions (methods of randomization, concealment of allocation to treatment groups), and the method of masking (blinding), based on the CONSORT Statement (http://www.consort-statement.org).
Reporting Guidelines for Specific Study Designs
Guideline |
Type of Study |
Source |
STROBE |
Observational studies including cohort, case-control, and cross-sectional studies |
https://www.strobe-statement.org/index.php?id=available-checklists |
CONSORT |
Randomized controlled trials |
|
SQUIRE |
Quality improvement projects |
http://squire-statement.org/index.cfm?fuseaction=Page.ViewPage&PageID=471 |
PRISMA |
Systematic reviews and meta-analyses |
|
STARD |
Studies of diagnostic accuracy |
|
CARE |
Case Reports |
|
AGREE |
Clinical Practice Guidelines |
https://www.agreetrust.org/wp-content/uploads/2016/02/AGREE-Reporting-Checklist-2016.pdf |
Statistics: Whenever possible quantify findings and present them with appropriate indicators of measurement error or uncertainty (such as confidence intervals). Authors should report losses to observation (such as, dropouts from a clinical trial). When data are summarized in the Results section, specify the statistical methods used to analyze them. Define statistical terms, abbreviations, and most symbols. Specify the computer software used.
: Present your results in a logical sequence in the text, tables, and illustrations. Do not repeat in the text all the data in the tables or illustrations.Extra- or supplementary materials and technical detail can be placed in an appendix where it will be accessible but will not interrupt the flow of the text; alternatively, it can be published only in the electronic version of the journal.
. Restrict tables and figures to those needed to explain the argument of the paper and to assess its support. Use graphs as an alternative to tables with many entries; do not duplicate data in graphs and tables. Where scientifically appropriate, analyses of the data by variables such as age and sex should be included.
Discussion: Include summary of key findings (primary outcome measures, secondary outcome measures, results as they relate to a prior hypothesis); Strengths and limitations of the study (study question, study design, data collection, analysis and interpretation); Interpretation and implications in the context of the totality of evidence (is there a systematic review to refer to, if not, could one be reasonably done here and now?, what this study adds to the available evidence, effects on patient care and health policy, possible mechanisms); Controversies raised by this study; and Future research directions (for this particular research collaboration, underlying mechanisms, clinical research).A following final conclusion should be stated.
Review Articles:
It is expected that these articles would be written by individuals who have done substantial work on the subject or are considered experts in the field. A short summary of the work done by the contributor(s) in the field of review should accompany the manuscript.
The review article should have an unstructured Abstract representing an accurate summary of the article. The section titles would depend upon the topic reviewed. Authors submitting review article should include a section describing the methods used for locating, selecting, extracting, and synthesizing data. These methods should also be summarized in the abstract.
The journal expects the contributors to give post-publication updates on the subject of review. The update should be brief, covering the advances in the field after the publication of the article and should be sent as a letter to editor, as and when major development occurs in the field.
Case reports:
New, interesting and rare cases can be reported. They should be unique, describing a great diagnostic or therapeutic challenge and providing a learning point for the readers. Cases with clinical significance or implications will be given priority. These communications could be of up to 1000 words (excluding Abstract and references) and should have the following headings: Abstract (unstructured), Key-words, Introduction, Case report, Discussion, Reference, Tables and Legends in that order.
The manuscript could be of up to 1000 words (excluding references and abstract) and could be supported with up to 10 references. Case Reports could be authored by up to four authors.
Other:
Editorial, Guest Editorial, Commentary and Opinion are solicited by the editorial board.
References
References should be numbered consecutively in the order in which they are first mentioned in the text (not in alphabetic order). Identify references in text, tables, and legends by Arabic numerals with square parenthesis [ ] and not superscript. References cited only in tables or figure legends should be numbered in accordance with the sequence established by the first identification in the text of the particular table or figure. Use the style of the examples below, which are based on Vancouver Numbered. The titles of journals should be abbreviated according to the style used in Index Medicus. Use complete name of the journal for non-indexed journals. Avoid using abstracts as references. Information from manuscripts submitted but not accepted should be cited in the text as "unpublished observations" with written permission from the source. Avoid citing a "personal communication" unless it provides essential information not available from a public source, in which case the name of the person and date of communication should be cited in parentheses in the text.
For example:
1 Stannard W, Rutman A, Wallis C, O'Callaghan C. Central microtubular agenesis causing primary ciliary dyskinesia. Am J Respir Crit Care Med. 2004;169:634-7.
Tables
Illustrations (Figures)
Sending a revised manuscript
The revised version of the manuscript should be submitted online in a manner similar to that used for submission of the manuscript for the first time. However, there is no need to submit the “First Page" or “Covering Letter" file while submitting a revised version. When submitting a revised manuscript, contributors are requested to include, the 'referees' remarks along with point to point clarification at the beginning in the revised file itself. In addition, they are expected to mark the changes as underlined or colored text in the article.
Manuscript submission, processing and publication charges
Submission charges: The journal does not charge for submission.
Processing and Publication charges: The journal will charge fee on acceptance for case Report, Short communication, Editorial, Original Article, Review Article, for the online publications. The article publication fee is 150$ USD. Further details are available upon the acceptance of the article.
Checklist
Covering letter
Authors
Presentation and format
Language and grammar
Tables and figures